Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 23;17(5):1308-1316.
doi: 10.5114/aoms.2019.83658. eCollection 2021.

Human papillomavirus infection predicts a better survival rate in patients with oropharyngeal cancer

Piotr Kędzierawski  1 , Anna Huruk-Kuchinka  1 , Agnieszka Radowicz-Chil  2 , Ryszard Mężyk  3 , Zdzisława Rugała  1 , Jacek Sadowski  1
Affiliations

Human papillomavirus infection predicts a better survival rate in patients with oropharyngeal cancer

Piotr Kędzierawski et al. Arch Med Sci. .

Abstract

Introduction: Squamous cell carcinoma is the most common malignant tumour occurring in the head and neck region. It is now understood that (human papillomavirus (HPV)- positive and HPV-negative diseases are two very different clinical entities associated with different outcomes. We decided to assess p16 expression status in patients with oropharyngeal cancer and retrospectively evaluate the outcomes of the treatment.

Material and methods: The evaluated group consisted of 98 consecutive patients with squamous cell carcinoma of the oropharynx treated in a combined way in Holycross Cancer Centre in Kielce in 2006-2014. For all patients p16 status was assessed based on the biological material. In 51 patients HPV infection was diagnosed. The Kaplan-Meier method was used to produce survival curves using the log-rank test and the Cox proportional hazard model was used to determine the risk factors. The following risk factors were included: HPV status (positive, negative), sex, age, smoking, histopathological grade of the tumour, clinical stage, and systemic therapy application. For HPV-positive and HPV-negative patients independent analyses were done including aforementioned factors, excluding HPV status.

Results: The observation time for HPV-positive patients was significantly longer (p = 0.0008). Fifty-eight patients died, 40 patients are alive. Number of deaths in HPV-negative patients was statistically significantly higher (p = 0.0222). A statistically significant difference in the disease-free survival probability and overall survival probability between HPV-positive and HPV-negative patients was found (p = 0.0045 and p = 0.0037 respectively). For disease-free survival a statistically significant factor of the risk of recurrence was HPV infection (p = 0.0169). For HPV-positive patients, age (p = 0.0199) and smoking (p = 0.0353) were statistically significant risk factors of recurrence. For HPV-negative patients significant risk factors of recurrence were clinical stage (p = 0.0114) and systemic therapy application (p = 0.0271). For overall survival for the entire group statistically significant risk factors were absence of HPV infection (p = 0.0123), male sex (p = 0.0426), and age (p = 0.0311). For HPV-positive patients, age (p = 0.0096) and smoking (p = 0.0387) were statistically significant risk factors of death. For HPV-negative patients significant risk factors of death were clinical stage (p = 0.0120) and systemic therapy application (p = 0.0460).

Conclusions: Our data show that HPV infection is a predictor of better disease-free and overall survival in patients with oropharyngeal cancer. For HPV-positive oropharyngeal cancer patients weekly given cisplatin with concurrent radiotherapy can be an alternative to three weekly given cisplatin considering effectiveness and early toxicity.

Keywords: head and neck cancer; human papillomavirus; radiochemotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Observation time in studied group of patients along with the division into HPV+ and HPV–
Figure 2
Figure 2
Disease-free survival (DFS) probability (%) of patients with oropharyngeal cancer with the division into HPV+ and HPV–
Figure 3
Figure 3
Overall survival (OS) probability (%) of patients with oropharyngeal cancer with the division into HPV+ and HPV–
See this image and copyright information in PMC

References

    1. Schiff BA. Overview of Head and Neck Tumors – Tumors of the Head and Neck. Merck Manual Professional Version; Available at: www.msdmanuals.com.
    1. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol. 2005;32(Suppl 1):59–66. - PubMed
    1. Nasman A, Attner P, Hammersted L, et al. Incidence of human papillomavirus (HPV)-positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125:362–6. - PubMed
    1. Psyrri A, Di Maio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol. 2007;5:24–31. - PubMed
    1. O’Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta- analysis. Oral Oncol. 2012;48:1191–201. - PubMed